Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®
Elaine S. DeMeyer, MSN, RN, AOCN®, BMTCN®, is the owner of beyond Oncology Education, LLC and has been a nurse entrepreneur for more than two decades. Elaine leverages her healthcare background along with creativity, business knowledge, and collaborative relationships.
Her mission through beyond Oncology is: To improve patient care by empowering oncology professionals with the tools and resources to change practice.
Articles by Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®
Oncology nurses may be the first to identify the classic triad of hyperviscosity syndrome symptoms.
Almost all patients with multiple myeloma at some point will develop bone disease—the “B” in CRAB.
Oncology nurses are integral to the success of ECP, as they provide ongoing education and psychosocial support to patients.
Before axatilimab, targeting the CSF-1R pathway was not previously studied in cGVHD.
New research and therapeutic approaches are challenging long-held beliefs about this type of graft.
Understanding critical symptoms in the “CRAB” acronym can enable oncology nurses to educate patients and caregivers.
Up to 50% of patients have renal insufficiency at the time of multiple myeloma diagnosis.
It's critical for oncology nurses to encourage these patients to monitor their blood pressure at home.
Renal toxicity occurs in approximately 75% of all patients who receive allogeneic stem cell transplants.
Learn how oncology nurses can address the challenges associated with early detection, diagnosis, and management.
It's critical for oncology nurses understand and recognize the 3 atypical lung cGVHD conditions.
Oncology nurses must familiarize themselves with CNS and PNS cGVHD to improve patient outcomes.
With better understanding of CNS cGVHD, oncology nurses can help ensure early recognition and reporting.
There are 5 types of immune-mediated cytopenias, each with provisional diagnostic criteria.
Nurses have a critical role in managing cGVHD-related serositis, including patient assessment, direct care, and education.
Since TAC levels must remain in a therapeutic range, oncology nurses often draw blood levels before the morning dose.
Although the term “atypical cGVHD” is imperfect, it describes a form of cGVHD that doesn’t fit neatly into classic ...
Currently, there is no standardization of melphalan administration.
With 3 FDA-approved BiTEs for myeloma, oncology nurses must be able to understand BiTEs and explain them to patients.
Misinformation or fake news can mislead patients with multiple myeloma.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.